N-11 truncated amyloid-beta monoclonal antibodies, compositions, methods and uses
CA 2498058 C · Owner: Mercken, Marc Hubert · Inventors: Mercken, Marc Hubert; Vandermeeren, Marc Maria Pierre Pelagie
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention relates to antibodies, including specified portions or variants, specific for at least the human Amyloid-beta 11 N-terminal site i.e. A.szlig.11-x peptides. It further provides methods of making and using said antibodies, including therapeutic formulations administration and , devices.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 9, 2003 and granted February 12, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended September 9, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 9, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.